As Connecticut experiences a surge in respiratory syncytial virus (RSV) cases, U.S. Sen. Richard Blumenthal called Monday on drug manufacturers AstraZeneca and Sanofi to address an ongoing shortage of a new monoclonal antibody meant to prevent the illness in infants.
